Protocol Ledger

NCT06695845 · Phase II · RECRUITING

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Interventional Phase II clinical trial protocol NCT06695845 sponsored by Jazz Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-14 Enrollment: 200 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06695845
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06695845
Protocol FieldVerified Registry Value
NCT IdentifierNCT06695845
Consolidated Lead SponsorJazz Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment200 participants (ESTIMATED)
Registered Start Date2025-01-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI